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This non-interventional post-authorisation safety study (PASS) assessed the long-term
safety of everolimus in patients with tuberous sclerosis complex (TSC) who participated
in the TuberOus SClerosis registry to increase disease Awareness (TOSCA) clinical study
and received everolimus for the licensed indications in the European Union. The rate of
adverse events (AEs), AEs that led to dose adjustments or treatment discontinuation,
AEs of potential clinical interest, treatment-related AEs (TRAEs), serious AEs (SAEs), and
deaths were documented. One hundred seventy-nine patients were included in the first 5
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years of observation; 118 of 179 patients had an AE of any grade, with the most common
AEs being stomatitis (7.8%) and headache (7.3%). AEs caused dose adjustments in
56 patients (31.3%) and treatment discontinuation in nine patients (5%). AEs appeared
to be more frequent and severe in children. On Tanner staging, all patients displayed
signs of age-appropriate sexual maturation. Twenty-two of 106 female (20.8%) patients
had menstrual cycle disorders. The most frequent TRAEs were stomatitis (6.7%) and
aphthous mouth ulcer (5.6%). SAEs were reported in 54 patients (30.2%); the most
frequent SAE was pneumonia (>3% patients; grade 2, 1.1%, and grade 3, 2.8%). Three
deaths were reported, all in patients who had discontinued everolimus for more than
28 days, and none were thought to be related to everolimus according to the treating
physicians. The PASS sub-study reflects the safety and tolerability of everolimus in the
management of TSC in real-world routine clinical practice.
Keywords: everolimus, TOSCA, tuberous sclerosis complex, post-authorization safety study, mammalian target
of rapamycin
INTRODUCTION
Tuberous sclerosis complex (TSC) is a rare, genetic, multisystem
disorder. TSC can affect almost any organ system, including
the skin, central nervous system, kidneys, eye, heart, and
lung. About 90% of the TSC patients experience neurological
and renal abnormalities, which represent a major cause of
morbidity and mortality (1, 2). The clinical presentation
of TSC is heterogeneous, and the degree of severity is
highly variable between individuals, even among the family
members (1). The onset of clinical manifestations of TSC also
typically varies with age, which further adds to the complexity
to the disease (3, 4). These factors represent a significant
challenge for the diagnosis and management of TSC. Current
management guidelines are focused on early identification and
close monitoring of lesion burden in combination with timely
medical treatment of manifestations and early interventions
for TSC-associated neuropsychiatric disorders (TANDs) (4).
TSC is caused by pathogenic variants in either TSC1 or
TSC2 genes, resulting in hyper-activation of the mammalian
target of rapamycin (mTOR) signalling pathway and the
subsequent development of hamartomatous lesions in patients
with TSC (4).
Based on double-blinded, placebo-controlled, randomised,
clinical trials that confirmed its safety and efficacy, the mTOR-
inhibitor everolimus (Votubia R©) was approved in Europe in
2011 for the treatment of subependymal giant cell astrocytoma
(SEGA) and renal angiomyolipoma (5–13). Randomised clinical
trial studies are required as “gold standard” for product
licensing. However, they fail to reflect the “real-world” scenarios,
particularly in terms of AE representation. The randomised
clinical trials have shown that everolimus was generally well-
tolerated in patients with TSC with manageable AEs, which were
generally reversible and non-cumulative (14–16). However, since
TSC is a rare disease, with a prevalence of 6.8–12.4 per 100,000
people (17), the three key registration trials included relatively
small numbers of patients with TSC [ranging from 78 in EXIST-1
to 247 in EXIST-3 (5, 9, 12)].
The TuberOus SClerosis registry to increase disease
Awareness (TOSCA) study was conducted to address existing
lacunas in the diagnosis and management of TSC. Based on
the request from European Medicines Agency (EMA) to use
the TOSCA registry to collect data on long-term safety and
reproductive abnormalities in patients taking everolimus for
licensed indications, SEGA in children age 2–20 years, and
angiomyolipoma in adults aged >18 years, the TOSCA post-
authorisation safety study (PASS) was developed. Here, we report
findings from this TOSCA sub-study.
METHODS
Study Design and Participants and Data
Collection
The TOSCA clinical study methodology has been published
previously (15). In brief, TOSCA was a large-scale non-
interventional study in patients with TSC. The study was
designed with a core section, six ancillary research projects
(with more detailed focus on SEGA, renal angiomyolipoma and
lymphangiomyomatosis, genetics, TAND, epilepsy, and patient’s
quality of life), and a PASS sub-study (EU PASS Register
Number EUPAS3247).
The TOSCA-PASS sub-study was aimed at collecting
prospective long-term safety data of treatment with everolimus
prescribed for the indications licensed in Europe at time of
enrolment data on AEs, therapeutic drug monitoring data, and
the long-term reproductive abnormalities within routine clinical
practice were collected. The PASS sub-study was conducted in 11
European Union countries participating in the TOSCA registry.
Patients
Patients who participated in the TOSCA registry and received
everolimus treatment in the licensed indications (for SEGA or
renal angiomyolipoma) in the European Union were eligible for
inclusion in the TOSCA PASS, after providing additional written
informed consent.
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The data collection cut-off was 10 August 2017 for
the TOSCA PASS sub-study. As per EMA indication
(EMA/CHMP/59467/2014, 20 February 2014), data collection
on sexual maturation and fertility is to be continued for all
paediatric patients until they reach Tanner stage 5, or age
16 years for females and age 17 years for males, whichever
occurs first.
For the TOSCA PASS sub-study, being a non-interventional
and observational study, all treatment-related decisions
(dose adjustments, treatment discontinuation) were at the
discretion of the treating physicians. No treatment protocol,
diagnostic/therapeutic procedure, or a formal visit schedule
was mandated by the TOSCA PASS study protocol. However,
the recommended data collection per study schedule was at
3-monthly intervals, which most likely mirrors the patterns
of routine clinical care of patients treated with everolimus.
Detailed management of each individual’s AEs was not collected;
however, general guidelines were followed by investigators (18).
Data were collected for all patients who achieved Tanner stage
5 by the cut-off date. For patients who discontinued the study
prematurely, the reason for discontinuation was determined.
All patients were instructed regarding possible AEs and their
possible treatment (19).
In this manuscript, we present an interim analysis of patient
data up to 10 August 2017. The long-term safety data of
these patients will be reported after termination of the TOSCA
PASS study.
Outcome Measures and Data Analysis
Incidence of AEs, AEs that lead to dose adjustment or
discontinuation, everolimus treatment-related AEs (TRAEs) as
per the investigator assessment, AEs of special interest (AESIs),
serious AEs (SAEs), and deaths were documented during
the treatment (from day of enrolling into the PASS study to
28 days after the last dose of everolimus). AESIs were those
AEs that were of specific clinical interest in connection with
everolimus treatment. Potential AEs sought included non-
infectious pneumonitis, severe infections, hypersensitivity
(anaphylactic reactions), stomatitis, wound healing
complications, increased serum creatinine/proteinuria/renal
failure, hyperglycaemia, new onset of diabetes mellitus,
dyslipidaemia, hypophosphatemia, cardiac failure, cytopenias,
haemorrhages, thrombotic and embolic events, female fertility
(including secondary amenorrhea), pre-existing infections
(reactivation/aggravation/exacerbation), safety in patients
with hepatic impairment, postnatal developmental toxicity,
pregnant or breast-feeding women, male infertility, and muscle
wasting/muscle loss. The relationship of the incidence of AESIs
with everolimus blood levels was also noted. SAEs were defined
as AEs that are fatal or life-threatening, result in persistent
or significant disability/incapacity, constitute a congenital
anomaly/birth defect, are medically significant, require medical
or surgical intervention, or require inpatient hospitalisation or
prolonged existing hospitalisation.
Data on everolimus (dose, interruption, dose change,
and duration) and concomitant medication were captured.
Concomitant medications entered into the database were coded
using the World Health Organization (WHO) drug reference
list, which employs the anatomical therapeutic chemical (ATC)
classification system.
The analysis set consisted of all patients who had at least
one post-baseline safety assessment and were exposed to at least
one dose of everolimus after the enrolment. The AEs and SAEs
were summarised by system organ class and preferred term using
the Medical Dictionary for Regulatory Activities (MedDRA)
version 20.
RESULTS
Patient Disposition and Baseline
Characteristics
A total of 179 patients were enrolled in the study. Of 179 patients,
16 patients (8.9%) had discontinued participation in the study,
and 31 patients continued to be followed up as part of the
ongoing paediatric PASS. Of the 16 patients who discontinued the
study, 12 were lost to follow-up, three died, and one patient was
withdrawn as per investigator’s decision (Figure 1). Everolimus
was initiated for 73 (40.8%) patients with SEGA, 122 (68.2%)
with renal angiomyolipoma, and 17 (9.5%) for both SEGA and
renal angiomyolipoma.
The demographic and clinical characteristics of the enrolled
patients are summarised in Table 1. Of 179 patients enrolled, 61
(34.1%) were children (<18 years), and 73 and 106 (59.2%) were
female. The median age at consent was 27 years (range < 1–
65 years). So far, all patients have reached their 1-year follow-
up visit; while 175, 158, 75, and 37 patients have completed
their second, third, fourth, and fifth annual follow-up visits,
respectively. Mutation testing was performed on 92 patients
(51.4%). The majority of patients, 71 (77.2%), had pathogenic
variants in TSC2, 8 (8.7%) had pathogenic variants in TSC1,
and 13 (14.1%) remained without genetic diagnosis (no mutation
identified or NMI).
Safety
Overall, 118 of 179 patients (65.9%) had AEs of any grade,
irrespective of its relationship with study drug (Table 2). The
most common grade 3/4 AE that occurred in >3% of patients
was pneumonia observed in 2.8% of patients (Table 3). The rate
of AEs was higher in children compared with adults [75.4% (n=
61) vs. 61.0% (n = 72); P = 0.0541], and a decreasing trend on
AE rate was noted with increase in age (Table 2).
The most frequent TRAEs were stomatitis (6.7%), aphthous
mouth ulcer (5.6%), and hypercholesterolaemia (5%). Everolimus
dose adjustments due to AEs were reported in 56 patients
(31.3%). The most common AEs that led to dose adjustments in
at least two patients were diarrhoea (five patients); stomatitis,
pneumonia, common cold, and urinary tract infection (three
patients each); and metrorrhagia, pyrexia, pyelonephritis,
sinusitis, influenza, and otitis (two patients each). Haemorrhagic
events leading to dose adjustments were haemorrhage on the
left side of the brain, bleeding in angiomyolipoma, and renal
haemorrhage (one patient each). AEs leading to everolimus
discontinuation were reported in nine patients (5%) and
included fatigue and amenorrhea (1.1% each); and anaemia,
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FIGURE 1 | Patient disposition in TOSCA PASS sub-study. TOSCA, TuberOus SClerosis registry to increase disease Awareness; PASS, post-authorisation
safety study.
mouth ulceration, empyema, pneumonia, hyperglycaemia, type I
diabetes mellitus, flank pain, intestinal adenocarcinoma, seizure,
and alopecia (0.6% each).
SAEs were reported in 54 patients (30.2%). The most frequent
SAE (>3% of patients) was pneumonia (grade 2, 1.1%; grade
3, 2.8%).
Three deaths were reported in the study. These deaths
occurred after 28 days of everolimus discontinuation and were
reported by study investigators as not related to everolimus
treatment. Patient 1, male, aged 30 years, from the Netherland,
died due to medically assisted death as per the local regulations
on day 487 after commencement of everolimus administration.
He had permanently discontinued everolimus treatment on
day 205. Patient 2, male aged 52 years, died from influenza
(grade 4) on day 1399; everolimus treatment was permanently
discontinued on day 1359. Patient 3, male aged 46 years,
died due to intestinal adenocarcinoma on day 74; everolimus
was permanently discontinued on day 43. Autopsy was not
performed for patients 1 and 2, whereas, this was unknown
for patient 3.
Everolimus Dosage and Exposure
Data on everolimus dosage and exposure were available for 150
patients. The mean duration of the everolimus exposure was
302.4 ± 105.04 days (median, 365 days; range, 7–669 days).
The mean and median daily doses and the most commonly
administered dosage (5mg throughout the study) are shown
in Table 4. The mean everolimus blood level at baseline was
6.27 ng/ml (median, 4.9 ng/ml; range, 1.4–35.9 ng/ml), with
the maximum concentration reported at third follow-up visit
(mean, 6.6 ng/ml) and the least at fourth follow-up visit (mean
4.937 ng/ml). Median duration of exposure in<18 years (n= 59)
and ≥18 (n = 91) was 365 days (P = 0.1735) with a significant
difference in mean daily everolimus dose of 6.4mg (range, 1–
13mg) in <18 years vs. 7.7mg (range, 1–20mg) in ≥18 years
(P = 0.0144), respectively. Changes in everolimus dosage were
reported in 53 patients (35.3%), with dose increase reported in
44 patients (83%), dose interruptions in 20 patients (13.3%),
and dose reductions in 14 patients (9.3%) (Table 4). The most
common reasons for dose changes were side effects (21 patients,
14%); other reasons are specified in Table 4.
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Age at consent, years
Mean (SD) 27.1 (16.08)
Median (range) 27.0 (<1–65)
Age groups, n (%)
≤2 years 7 (3.9)
>2 to ≤5 years 6 (3.4)
>5 to ≤9 years 21 (11.7)
>9 to ≤14 years 16 (8.9)
>14 to ≤18 years 11 (6.1)
≥18 to ≤40 years 77 (43.0)







Czech Republic 3 (1.7)
Slovenia 3 (1.7)




Patients with molecular testing, n (%) 92 (51.4)
TSC1 mutation 8 (8.7)
TSC2 mutation 71 (77.2)
No mutation identified 13 (14.1)
TSC manifestations, n (%)
Neurological
SEGA 100 (55.9)
Cortical tuber 147 (82.1)
SEN 156 (87.2)
Cerebral white matter radial migration lines 24 (13.4)
Renal
Renal angiomyolipoma 149 (83.2)
Multiple renal cysts 53 (29.6)
Polycystic kidneys 4 (2.2)
Impaired renal function 5 (2.8)




Cardiac rhabdomyoma 51 (28.5)
Dermatologic
≥3 hypomelanotic macules 84 (46.9)
Facial angiofibroma 123 (68.7)
(Continued)
TABLE 1 | Continued
Characteristics Patients
N = 179
Shagreen patch 42 (23.5)
Ungual or periungual fibromas 44 (24.6)
Forehead plaque 19 (10.6)
Confetti lesions 16 (8.9)
Ophthalmologic
Retinal hamartoma 32 (17.9)
Epilepsy 151 (84.4)
SD, standard deviation; SEGA, subependymal giant cell astrocytoma; SEN,
subependymal nodule; TSC, tuberous sclerosis complex.
Correlations Between Everolimus Blood
Levels and Adverse Events of Special
Interest
AESIs were reported in 57 of 150 patients (38%) for whom data
on everolimus dosage and exposure are available. AESIs were
suspected to be everolimus-related in 40 patients (26.7%). The
majority of the patients had grade 1 or grade 2 AEs. One patient
reported grade 4 empyema.Most of the patients who experienced
AESIs had everolimus concentration <8 ng/ml (24%). No
significant correlation was observed between everolimus blood
concentration and AESIs (Table 5).
Sexual Maturation and Menstrual
Irregularities
Tanner staging was performed in 28 patients (15.6%; three male
and 25 females). There were no significant delays in sexual
maturation revealed (Table 6). Nineteen females (17.9%) used
contraception, with the most commonly contraception being
hormone-based contraception in 16 patients (84.2%). Overall,
three patients (1.7%) had ovariectomy, and five (2.8%) used
external sex hormones (Table 6).
Of the 179 patients enrolled, 22 of 106 (20.8%) female patients
had menstrual cycle disorders. Amenorrhea was reported in
nine patients (8.5%) and other abnormal reproductive conditions
in three patients (1.7%). In the initial analysis, three patients
(1.7%, one male and two females) were reported to have
abnormal onset of puberty. However, on further analysis, it was
noted that one female child had precocious puberty, which was
treated successfully 5 years before starting everolimus treatment.
The second patient, a male child, had developed behavioural
problems during puberty, which were thought to be secondary
to oxcarbazepine and predated everolimus treatment. The third
patient, an adult female patient, had abnormal puberty before the
start of everolimus too. Thus, abnormal puberty was found to be
not related to everolimus treatment.
Abnormal hormone levels of thyroid-stimulating hormone
were reported in four patients (2.2%); testosterone levels were
abnormal in two patients (1.1%); luteinising hormone, follicular-
stimulating hormone, and oestradiol were abnormal in one
patient (0.6%) (Table 6).
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Overall, any AEs 118 (65.9) 6 (85.7) 21 (77.8) 19 (70.4) 72 (61)
Patients with frequent (>3%) adverse events with CTC grade
Grade 1 40 (22.3) 2 (28.6) 8 (29.6) 8 (29.6) 22 (18.6)
Grade 2 27 (15.1) 1 (14.3) 2 (7.4) 4 (14.8) 20 (16.9)
Grade 3 16 (8.9) 2 (28.6) 5 (18.5) 2 (7.4) 7 (5.9)
Grade 4 2 (1.1) 0 0 0 2 (1.7)
Patients with grade 3/4 AEs 43 (24.0) 4 (57.1) 8 (29.6) 6 (22.2) 25 (21.2)
Patients with SAE 54 (30.2) 5 (71.4) 12 (44.4) 7 (25.9) 30 (25.4) 0.0567
AE requiring dose adjustment 56 (31.3) 5 (71.4) 10 (37.0) 9 (33.3) 32 (27.1) 0.1342
AE leading to discontinuation 9 (5.0) 1 (14.3) 1 (3.7) 1 (3.7) 6 (5.1) 0.8357
Treatment-related AE 76 (42.5) 6 (85.7) 15 (55.6) 16 (59.3) 39 (33.1) 0.0023
Deaths 3 (1.7) 0 0 0 3 (2.5)
AE, adverse event; CTC, Common Terminology Criteria; SAE, serious adverse events.
TABLE 3 | Adverse events of any cause (by preferred term) reported in >3% of patients in overall population and across age groups.
Adverse events Overall N = 179 Age at consent, years
≤2 >2 to ≤9 >9 to <18 ≥18
(N = 7) (N = 27) (N = 27) (N = 118)
All Grade 3/4 All Grade 3/4 All Grade 3/4 All Grade 3/4 All Grade 3/4
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Stomatitis 14 (7.8) 1 (0.6) 1 (14.3) 0 3 (11.1) 1 (3.7) 5 (18.5) 0 5 (4.2) 0
Headache 13 (7.3) 0 0 0 0 0 3 (11.1) 0 10 (8.5) 0
Diarrhoea 12 (6.7) 1 (0.6) 1 (14.3) 0 3 (11.1) 0 1 (3.7) 0 7 (5.9) 1 (0.8)
Vitamin D deficiency 12 (6.7) 0 0 0 0 0 0 0 12 (10.2) 0
Aphthous ulcer 10 (5.6) 0 0 0 2 (7.4) 0 1 (3.7) 0 7 (5.9) 0
Hypercholesterolaemia 10 (5.6) 0 2 (28.6) 0 3 (11.1) 0 2 (7.4) 0 3 (2.5) 0
Urinary tract infection 10 (5.6) 1 (0.6) 1 (14.3) 1 (14.3) 0 0 1 (3.7) 0 8 (6.8) 0
Pyrexia 9 (5.0) 0 3 (42.9) 0 3 (11.1) 0 2 (7.4) 0 1 (0.8) 0
Hypertension 8 (4.5) 2 (1.1) 0 0 0 0 1 (3.7) 0 7 (5.9) 2 (1.7)
Pneumonia 8 (4.5) 5 (2.8) 2 (28.6) 1 (14.3) 2 (7.4) 2 (7.4) 1 (3.7) 0 3 (2.5) 2 (1.7)
Viral upper respiratory tract infection 8 (4.5) 0 0 0 1 (3.7) 0 1 (3.7) 0 6 (5.1) 0
Abdominal pain 7 (3.9) 1 (0.6) 0 0 2 (7.4) 1 (3.7) 0 0 5 (4.2) 0
Anaemia 7 (3.9) 1 (0.6) 0 0 1 (3.7) 0 1 (3.7) 0 5 (4.2) 1 (0.8)
Bronchitis 7 (3.9) 0 2 (28.6) 0 3 (11.1) 0 1 (3.7) 0 1 (0.8) 0
Oedema peripheral 7 (3.9) 0 0 0 1 (3.7) 0 0 0 6 (5.1) 0
Epilepsy 6 (3.4) 2 (1.1) 1 (14.3) 1 (14.3) 1 (3.7) 0 1 (3.7) 0 3 (2.5) 1 (0.8)
Hypertriglyceridaemia 6 (3.4) 2 (1.1) 0 0 0 0 4 (14.8) 2 (7.4) 2 (1.7) 0
Influenza 6 (3.4) 3 (1.7) 1 (14.3) 1 (14.3) 1 (3.7) 0 0 0 4 (3.4) 2 (1.7)
Vomiting 6 (3.4) 1 (0.6) 1 (14.3) 0 3 (11.1) 1 (3.7) 0 0 2 (1.7) 0
DISCUSSION
Based on the understanding of the TSC pathogenesis, the role of
everolimus in the management of different TSC manifestations
has been extensively evaluated. Studies evaluating everolimus
in the treatment of SEGA, angiomyolipoma, and epilepsy have
consistently demonstrated its efficacy and tolerability (6–8)
which subsequently led to the approval of everolimus in the
treatment of these TSC manifestations (14). Studies have also
shown that even with prolonged treatment, no new toxicities
or complications were observed (6, 10, 11, 13, 20). All these
data were obtained from interventional controlled clinical trials.
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TABLE 4 | Everolimus dosage and exposure.
Baseline FU1 FU2 FU3 FU4 FU5
(N = 150) (N = 171) (N = 168) (N = 153) (N = 58) (N = 33)
Pharmaceutical formulation
Tablets 143 (95.3) 165 (96.5) 162 (96.4) 147 (96.1) 56 (96.6) 33 (100.0)
Dispersible tablets 9 (6.0) 9 (5.3) 8 (4.8) 10 (6.5) 3 (5.2) 0
Dosage
2mg 3 (2.0) 3 (1.8) 3 (1.8) 3 (2.0) 0 0
2.5mg 16 (10.7) 13 (7.6) 19 (11.3) 17 (11.1) 6 (10.3) 2 (6.1)
3mg 2 (1.3) 3 (1.8) 2 (1.2) 2 (1.3) 1 (1.7) 0
5mg 118 (78.7) 131 (76.6) 128 (76.2) 114 (74.5) 43 (74.1) 31 (93.9)
10mg 17 (11.3) 18 (10.5) 16 (9.5) 16 (10.5) 4 (6.9) 0
Other 34 (22.7) 37 (21.6) 25 (14.9) 18 (11.8) 6 (10.3) 0
Daily dose (mg)
Mean (SD) 7.2 (3.11) 7.3 (3.14) 7.1 (3.28) 7.4 (4.27) 7.8 (3.40) 8.3 (3.99)
Median (min–max) 7.0 (1–20) 7.5 (1–20) 6.4 (0–20) 5.8 (0–35) 7.5 (3–15) 7.5 (3–15)
Patients with dose changes 53 (35.3) 55 (32.2) 52 (31.0) 34 (22.2) 19 (32.8) 0
Reductions 14 (9.3) 15 (8.8) 24 (14.3) 9 (5.9) 3 (5.2) 0
Interruptions 20 (13.3) 31 (18.1) 26 (15.5) 22 (14.4) 10 (17.2) 0
Increased 44 (29.3) 41 (24.0) 34 (20.2) 23 (15.0) 17 (29.3) 0
Reasons for changes
Side effect 21 (14.0) 25 (14.6) 22 (13.1) 11 (7.2) 2 (3.4) 0
Dosing error 3 (2.0) 1 (0.6) 1 (0.6) 0 0 0
Lab test abnormality 2 (1.3) 4 (2.3) 1 (0.6) 0 0 0
Concomitant medication affecting drug exposure 1 (0.7) 2 (1.2) 0 0 0 0
Other 30 (20.0) 30 (17.5) 24 (14.3) 20 (13.1) 10 (17.2) 0
FUP, follow-up; SD, standard deviation.
TABLE 5 | Correlation between everolimus exposure and incidence of AESIs at baseline.
Time from baseline visit Patients with AESI Everolimus concentration (ng/ml), n (%) P-value
<3 3 to <7 7 to <9 9 to ≤15 >15
Quarter 1 (n = 57) Yes 4 (7) 10 (17.5) 0 1 (1.8) 0 0.1673
No 12 (21.1) 15 (26.3) 7 (12.3) 4 (7) 4 (7)
Quarter 2 (n = 59) Yes 4 (6.8) 11 (18.6) 3 (5.1) 2 (3.4) 0 0.7195
No 10 (16.9) 19 (32.2) 3 (5.1) 5 (8.5) 2 (3.4)
Quarter 3 (n = 71) Yes 5 (7) 9 (12.7) 0 5 (7) 1 (1.4) 0.2557
No 8 (11.3) 24 (33.8) 9 (12.7) 7 (9.9) 3 (4.2)
Quarter 4 (n = 67) Yes 4 (6) 8 (11.9) 3 (4.5) 4 (6) 0 0.4535
No 7 (10.4) 24 (35.8) 7 (10.4) 5 (7.5) 5 (7.5)
Quarters 1 to 4 denote the quarter of year at the baseline visit. An event is mapped into Q j of Baseline if its start date is prior to Baseline date + 3 multiply by j months/Baseline date +
(3 multiply by j + 12) months and {its stop date is on or after the Baseline date + 3 multiply by (j – 1) months/Baseline date + [3 multiply by (j – 1) + 12] months or the event is ongoing},
where j = 1, 2, 3, 4.
AESI, adverse event of special interest.
There was a need of real-world evidence on the safety of
everolimus. Based on European Medical Agency indications
to Novartis (EMA/CHMP/59467/2014, 20 February 2014), the
PASS sub-study was performed as part of the TOSCA registry,
to evaluate real-world evidence on the safety of everolimus in
patients with TSC from 11 European countries. The number
of patients recruited in this study varied between participating
countries. In addition, as the recruitment was voluntary, the
study population does not mirror the prevalent TSC population
in each country.
In line with the previously reported everolimus in TSC studies
(6–8), the most commonly reported AE was stomatitis, which


































TABLE 6 | Sexual maturation and menstrual irregularities across age groups.

















Total patients evaluated for Tanner stages 28 (15.6) 0 1 (6.7) 4 (19.0) 10 (62.5) 6 (54.5) 6 (7.8) 1 (2.4)
Male patients with Tanner stages evaluated 3 (10.7) 0 0 2 (50.0) 1 (10.0) 0 0 0
Male patients with genitalia stage 3 (4.1) 0 0 2 (14.3) 1 (20.0) 0 0 0
Stage 1 0 0 0 0 0 0 0 0
Stage 2 0 0 0 1 (50.0) 0 0 0 0
Stage 3 1 (33.3) 0 0 0 1 (100.0) 0 0 0
Stage 4 1 (33.3) 0 0 1 (50.0) 0 0 0 0
Stage 5 1 (33.3) 0 0 0 0 0 0 0
Patients with pubic hair stage 3 (4.1) 0 0 2 (14.3) 1 (20.0) 0 0 0
Stage 1 1 (33.3) 0 0 0 0 0 0 0
Stage 2 1 (33.3) 0 0 1 (50.0) 0 0 0 0
Stage 3 2 (66.7) 0 0 0 1 (100.0) 0 0 0
Stage 4 0 0 0 0 0 0 0 0
Stage 5 1 (33.3) 0 0 1 (50.0)
Female patients with Tanner stages evaluated 25 (89.3) 0 1 (16.7) 2 (50.0) 9 (90.0) 6 (100.0) 6 (100.0) 1 (100.0)
Patients with breast stage 23 (21.7) 0 1 (33.3) 2 (28.6) 8 (72.7) 7 (70.0) 5 (10.2) 1 (4.0)
Stage 1 2 (8.7) 0 1 (100.0) 1 (50.0) 0 0 0 0
Stage 2 1 (4.3) 0 0 0 0 1 (16.7) 0 0
Stage 3 3 (13.0) 0 0 0 3 (37.5) 0 0 0
Stage 4 3 (13.0) 0 0 1 (50.0) 2 (25.0) 0 0 0
Stage 5 14 (60.9) 0 0 0 3 (37.5) 5 (83.3) 5 (100.0) 1 (100.0)
Patients with pubic hair stage 24 (22.6) 0 1 (33.3) 2 (28.6) 9 (81.8) 7 (70.0) 5 (10.2) 1 (4.0)
Stage 1 2 (8.3) 0 0 1 (50.0) 0 1 (16.7) 0 0
Stage 2 2 (8.3) 0 0 0 2 (22.2) 0 0 0
Stage 3 3 (12.5) 0 1 (100.0) 0 2 (22.2) 0 0 0
Stage 4 1 (4.2) 0 0 0 1 (11.1) 0 0 0
Stage 5 16 (66.7) 0 0 1 (50.0) 4 (44.4) 5 (83.3) 5 (100.0) 1 (100.0)
Contraception use
Patients who used contraception 19 (17.9) 0 0 1 (14.3) 0 2 (25.0) 12 (24.5) 4 (16.0)
Patients with hormone-based contraception 16 (84.2) 0 0 1 (100.0) 0 2 (100.0) 10 (83.3) 3 (75.0)
Type of hormone-based contraception
Ethinyl oestradiol/progestin combination
Overall 8 (50.0) 0 0 0 0 1 (50.0) 5 (50.0) 2 (66.7)
>50 µg of ethinyl oestradiol 3 (37.5) 0 0 0 0 0 2 (40.0) 1 (50.0)




















































































TABLE 6 | Continued


















Overall 8 (50.0) 0 0 1 (100.0) 0 1 (50.0) 5 (50.0) 1 (33.3)
Pill 4 (50.0) 0 0 1 (100.0) 0 0 3 (60.0) 0
Intrauterine devices 0 0 0 0 0 0 0 0
Depot injection 3 (37.5) 0 0 0 0 1 (100.0) 1 (20.0) 1 (100.0)
Implant 1 (12.5) 0 0 0 0 0 1 (20.0) 0
Use of external sex hormone that influence reproduction 5 (2.8) 0 0 0 0 1 (9.1) 2 (2.6) 2 (4.9)
Exogenous oestrogen 1 (20) 0 0 0 0 0 0 1 (50.0)
Progestin based to suppress menstruation 4 (80.0) 0 0 0 0 1 (100.0) 2 (100.0) 1 (50.0)
Patients with ovariectomy 3 (1.7) 0 0 0 1 (6.3) 0 2 (2.6) 0
Puberty abnormal 3 (1.7) 0 0 0 1 (6.3) 2 (18.2) 1 (1.3) 0
Male 1 (33.3) 0 0 0 0 1 (50.0) 0 0
Female 2 (66.7) 0 0 0 1 (100.0) 1 (50.0) 1 (100.0) 0
Menstrual cycle disorder (female > 11 years) 22 (20.8) 0 0 0 3 (27.3) 1 (12.5) 5 (11.6) 4 (16.0)
Amenorrhea (female > 11 years) 9 (8.5) 0 0 0 1 (9.1) 0 2 (4.7) 4 (16.0)
Amenorrhea lasted > 3 months 5 (55.6) 0 0 0 0 0 2 (100.0) 2 (50.0)
Other abnormal reproductive condition 3 (1.7) 0 0 0 2 (12.5) 0 1 (1.3) 0
Abnormal hormonal levels
Thyroid-stimulating hormone 4 (2.2) 0 0 0 1 (6.3) 0 1 (1.3) 2 (4.9)
Follicular-stimulating hormone 1 (0.6) 0 0 0 0 0 0 1 (2.4)
Luteinising hormone 1 (0.6) 0 0 0 0 0 1 (1.3) 0
Oestradiol 1 (0.6) 0 0 0 0 0 1 (1.3) 0
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is effectively managed to minimise the occurrence and severity
in TSC patients. The incidence of stomatitis and infections was
relatively low in this PASS sub-study (7.8 and 34%) than in the
previous EXIST studies (5, 6, 9, 12). Rates of stomatitis in EXIST-
1 and EXIST-2 were 31 and 48%, respectively (6, 8). Overall,
55–68% of patients had stomatitis in EXIST-3, which included
stomatitis, mouth, aphthous, lip, and tongue ulcerations; mucosal
inflammation; and gingival pain (5, 9, 12, 21). The decrease in
AEs like stomatitis with longer follow-up could be attributed to
better tolerability or better care or both (10). Additionally, the
median dose of everolimus was similar to that in the EXIST
interventional studies, whereas, the starting doses in the current
study were lower, as suggested by 44 patients having their
dose increased. In addition, outside of a strict trial protocol,
physicians may have been able to interrupt and reduce the dose
of everolimus to manage AEs. The rate of infections was reported
in about 72% patients in EXIST-1 and 65% of patients in EXIST-2
(8, 11). Similarly, the rate of infections was higher in the EXIST-3
study with nasopharyngitis in 14–23.8%, upper respiratory tract
infection in 13–22.4%, and pharyngitis 1–10.2% of the patients
(12, 21). However, the incidence of diarrhoea (6.7%) was slightly
higher than that reported in the EXIST-3 study (5%) but lower
than that of the EXIST-1 and EXIST-2 studies (13% each) (6–
8). Notably, PASS sub-study also showed a higher incidence
of AEs in children than in the adults (Table 2), as previously
reported in the EXIST-1 study (16, 22). It was unknown whether
this was due to higher blood levels or increased susceptibility
to everolimus.
No new safety signals were observed in the study. Most
of the AEs observed in the study were manageable with
dose adjustment and/or use of concomitant medication and
were of modest severity, with grade 1 or 2 AEs observed
in almost 42% of patients. The lower rate of stomatitis
or aphthous mouth ulceration and some other AEs in this
study compared with that expected from the literature could
be due to several reasons including lower starting doses,
early interruption or reduction of dose, better education and
preparation of patients, or lower median blood concentration
of everolimus in TOSCA PASS compared with those of the
previous interventional trials (9, 12, 20). In general, there was
likely to be a correlation between drug levels and AEs within
individual patients as evidenced by the successful treatment of
AEs by lowering the patients’ dose (Table 4), but it appears
that the different individuals have different sensitivities to any
particular blood level of everolimus causing AEs. Three deaths
were reported during the study. All occurred in adult patients
and were deemed by the study investigators as not related to
everolimus treatment.
The data on menstrual irregularities concur with the previous
findings with respect to clinical features but at lower frequency
(9) and confirm that everolimus can cause amenorrhoea
and other menstrual irregularities. In most patients, sexual
maturation was not affected by everolimus.
In conclusion, the findings from this study are confirmed the
manageable safety profile of everolimus in patients with TSCwith
no new safety signal. The long-term safety data will continue to
be collected as per study protocol for the paediatric patients.
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